| Exendin PET/CT for Imaging of Paragangliomas (NCT05418907) | Radboud University Medical Center | 2022-06-01 |
| A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL (NCT05883085) | Peking Union Medical College Hospital | 2022-05-01 |
| 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor (NCT05069220) | Peking Union Medical College Hospital | 2021-09-01 |
| Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (NCT04400474) | Grupo Espanol de Tumores Neuroendocrinos | 2020-10-07 |
| Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents (NCT03923257) | Sue O'Dorisio | 2020-08-04 |
| A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (NCT04187404) | Enterome | 2020-07-23 |
| Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT) (NCT04605848) | University of Avignon | 2020-07-03 |
| Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. (NCT04276597) | Excel Diagnostics and Nuclear Oncology Center | 2020-03-04 |
| Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics (NCT06669481) | Peking Union Medical College Hospital | 2020-01-01 |
| Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease (NCT04891081) | University Medical Centre Ljubljana | 2019-11-01 |
| Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging (NCT04017104) | British Columbia Cancer Agency | 2019-11-01 |
| 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. (NCT04081701) | Weill Medical College of Cornell University | 2019-09-04 |
| LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (NCT03946527) | Antonio Fojo | 2019-06-17 |
| Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma (NCT03839498) | Columbia University | 2019-01-22 |
| Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma (NCT05082311) | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 2019-01-19 |
| DOTATOC PET/CT for Imaging NET Patients (NCT03583528) | British Columbia Cancer Agency | 2018-07-11 |
| Multicenter Pheochromocytoma and Paraganglioma Evaluation (NCT03344016) | Felix Beuschlein | 2017-11-01 |
| Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma (NCT03206060) | National Cancer Institute (NCI) | 2017-10-10 |
| F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma (NCT05948137) | Asan Medical Center | 2017-09-21 |
| A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer (NCT03165721) | National Cancer Institute (NCI) | 2017-08-16 |
| Preoperative Alpha Blockade for Pheochromocytoma (NCT03176693) | University of California, Los Angeles | 2017-05-05 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (NCT02834013) | National Cancer Institute (NCI) | 2017-01-30 |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma (NCT01941849) | University College, London | 2014-10-01 |
| GA-68 DOTA-TOC of Somatostatin Positive Malignancies (NCT02177773) | University of California, San Francisco | 2014-06-23 |
| Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma (NCT01967576) | National Cancer Institute (NCI) | 2013-10-19 |
| Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (NCT01560260) | National Cancer Institute (NCI) | 2012-03-01 |
| Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma (NCT01340794) | National Cancer Institute (NCI) | 2011-05-01 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (NCT01204476) | National Cancer Institute (NCI) | 2010-10-01 |
| A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma (NCT00874614) | Molecular Insight Pharmaceuticals, Inc. | 2009-06-04 |
| Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma (NCT00911729) | Molecular Insight Pharmaceuticals, Inc. | 2009-04-01 |
| Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma (NCT00843037) | University Health Network, Toronto | 2009-02-01 |
| Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma (NCT01022515) | University Hospital, Rouen | 2008-11-01 |
| Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma (NCT00458952) | Molecular Insight Pharmaceuticals, Inc. | 2007-04-01 |
| Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers (NCT00188019) | University Hospital, Angers | 2005-11-01 |
| Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions (NCT03160274) | The University of Texas Health Science Center at San Antonio | 2005-10-19 |
| A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors (NCT01413503) | University of California, San Francisco | 1991-05-01 |
| 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors (NCT01373736) | Vancouver Coastal Health | |
| Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma (NCT02961491) | Molecular Insight Pharmaceuticals, Inc. | |
| Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma (NCT01838187) | Children's Hospital Medical Center, Cincinnati | |
| Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma (NCT01377532) | University of California, San Francisco | |
| Expanded Access Protocol Using 131I-MIBG (NCT01590680) | Jubilant DraxImage Inc. | |